F

Fraser Health

Public health authority operating hospitals

Licensed Practical Nurse - Transcranial Magnetic Stimulation

Full-TimeDeadline 7/21/27
CA$32.84 - CA$44.96/hr
Mid
New Westminster, BC, Canada
In PersonMay be required to travel to other sites as needed.
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • Current practicing registration as a Licensed Practical Nurse with the British Columbia College of Nurses and Midwives.
  • Successful completion of additional education in Mental Health and Substance Use as per the British Columbia College of Nurses and Midwives limits and conditions for licensed practical nurses.
  • Successful completion of additional training in Transcranial Magnetic Stimulation.
  • Two years of recent experience providing acute or community health nursing care or services, or an equivalent combination of education, training, and experience.
  • Demonstrated ability in nursing practice related to clients with psychiatric illness who are undergoing Transcranial Magnetic Stimulation.
  • Demonstrated knowledge of concurrent disorders, substance use and abuse, and harm reduction strategies, including assessment and intervention.
  • Demonstrated knowledge of the principles and practices of conceptual models of psychiatric care, including person- and family-centered care, the recovery-oriented model in mental illness, and psychosocial rehabilitation methodology.
  • Demonstrated knowledge of the Mental Health Act as it applies to the rights and obligations of clients and staff.
  • Demonstrated skill in nursing within an autonomous scope of practice and adherence to standards of care relevant to the designated client population.
  • Demonstrated skills in cardiopulmonary resuscitation techniques.
  • Demonstrated ability to participate in the development and delivery of educational programs and materials for clients and families based on educational theories, principles, and best practices.
  • Demonstrated computer literacy to operate a computerized client care information system and applicable word-processing, spreadsheet, and database software applications.
  • General knowledge of Trauma-Informed Practice and strengths-based care.
  • Demonstrated ability to promote Indigenous Cultural Safety.
  • Demonstrated ability to provide competent and culturally safe care in a variety of settings and with diverse populations.
  • Physical ability to perform the duties of the position.
Responsibilities
  • Provide individualized direct nursing care to clients undergoing Transcranial Magnetic Stimulation for conditions including treatment-resistant depression, including physical and psychosocial screening and assessments and participation in developing and revising client treatment and interdisciplinary care plans with clients, families, and providers.
  • Advocate for and facilitate informed choices and consent; educate clients and families about the purpose, risks, benefits, implications, and potential side effects of Transcranial Magnetic Stimulation, the right to withdraw consent, and management and other treatment options for the medical conditions being treated.
  • Establish therapeutic relationships with clients and families and provide emotional support by identifying their perspectives, learning needs, readiness, and ability to learn; discuss and incorporate their priorities, wishes, and goals into care plans; monitor client progress against treatment goals and time frames.
  • Consult, confer, and collaborate with peers and other caregivers to identify and resolve client and family care concerns, consent and special-population issues, ethical dilemmas, and care coordination and integration; collaborate with the interdisciplinary care team in rounds and client care conferences; advocate for client autonomy, respect, privacy, dignity, and access to information.
  • Document client and family perspectives, nursing assessments, education provided, and activities supporting their priorities; ensure pre-procedure assessment findings and valid informed consent are documented as applicable; maintain client health records to professional and organizational standards, including documenting care, communicating risk, preparing regulatory reports, and providing evidence and rationale for client-centered care and treatment planning.
  • Administer Transcranial Magnetic Stimulation using the electronic device according to client-specific orders and physician-specified clinical treatment parameters; monitor client response and side effects and escalate concerns appropriately.
  • Use appropriate supplies and equipment while considering cost, availability, and safe-care requirements; maintain equipment and troubleshoot malfunctions with technical staff; handle, store, and dispose of hazardous workplace materials and sharps according to established procedures and policies.
  • Identify significant or life-threatening changes in client condition and escalate them to a Registered Nurse or Physician; intervene as directed, evaluate outcomes, initiate appropriate hospital response resources during critical events, resolve emergencies in collaboration with nursing or physician staff, assess clients for transfer using established criteria, and provide a systematic report to receiving-unit nursing staff.
  • Respond to incidents including staff or visitor injuries, Code Blue or Code White emergencies, hazardous spills, fire, and aggressive or disruptive behavior to ensure timely medical and other support; inform designated staff and complete incident reports according to established procedures and policies.
  • Conduct psychosocial assessments and work with the multidisciplinary team to provide trauma-informed, culturally safe, recovery-oriented, and evidence-informed care to clients with impaired functioning related to mental and emotional distress or crisis; address altered thinking and self-concept, behaviors indicating danger to self or others, and side effects or toxicities from psychopharmacologic interventions if used; escalate care to a Registered Nurse or Physician as required.
  • Screen referrals for Transcranial Magnetic Stimulation treatment with the Physician using inclusion and exclusion criteria; communicate referral status to referring providers; facilitate discharge planning and referrals to community services.
  • Support appointment scheduling and coordination; with a Registered Nurse or Physician, prioritize emergent situations against routine procedures in response to fluctuating workload volumes and client treatment requirements, in consultation with team members.
  • Participate in program development by attending meetings, drafting or revising client care plans for program leadership review, and providing input to improve client and family care and the efficient and safe operation of the unit.
  • Guide the clinical experience of assigned students and new staff and help orient new hires to unit policies and procedures.
  • Set measurable professional-development goals with the Manager, update own knowledge by reviewing current literature and research, identify new theories, trends, and opportunities, and develop a professional-development plan with the Clinical Nurse Educator and Manager.
  • Apply a research approach to clinical problem-solving by reviewing relevant literature and resources and applying research findings within established procedures or in collaboration with a Clinical Nurse Specialist, Operations Manager, Coordinator, or Clinical Nurse Educator; evaluate results.
  • Participate in approved nursing and interdisciplinary research and special projects with other health care professionals, including collecting, integrating, and interpreting data, summarizing information, and providing updates for review and further analysis by the principal researcher, research team, or project coordinator.
  • Perform other related duties as assigned.

About the company

Fraser Health is a health authority in British Columbia that provides a wide range of medical services to about 1.8 million people. It operates 12 hospitals, including major trauma centres, plus an outpatient care and surgery centre, and offers residential care, home health, public health, and mental health services. The organization employs over 40,000 staff, medical professionals, and volunteers who run clinics, care centres, and community programs. Its goal is to deliver accessible, high-quality care across the network while creating good workplaces for its employees and volunteers.

Company Size

10,001+

Company Stage

Grant

Total Funding

$20K

Headquarters

Surrey, Canada

Founded

2001

Get referred to Fraser Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The $18 million Mission Memorial ED expansion started construction in February 2026.
  • The Cloverdale UPCC opened January 28, 2026, with capacity for 64,000 annual visits.
  • Fraser Health won $1.3 million in March 2026 to expand Indigenous elder home care in Chilliwack.

What critics are saying

  • Mission Memorial ED faced repeated overnight shutdowns in May, June, and August 2026.
  • Physician staffing gaps still force service interruptions, signaling fragile emergency coverage across the network.
  • The Cloverdale hospital slipped from 2027 to 2030, weakening growth and credibility.

What makes Fraser Health unique

  • Fraser Health runs 12 hospitals and serves 1.8 million people across British Columbia.
  • Its Mission ED expansion adds 35% more space and reaches 41 care spaces by spring 2027.
  • Deloitte-backed AI scheduling models forecast patient surges and staffing demand across Fraser Health.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
StockTitan
Mar 24th, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial.

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial. Rhea-AI Impact Rhea-AI Sentiment Rhea-AI summary. Arch Biopartners (OTCQB: ACHFF) announced a Clinical Trial Agreement with Fraser Health Authority to prepare Royal Columbian Hospital for recruitment in its Phase II trial of LSALT peptide for prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). Royal Columbian Hospital is now the ninth global site activated and the fourth Canadian recruiting site, after Toronto General Hospital, St. Michael's Hospital, and University of Calgary. Positive. * Royal Columbian Hospital received final Research Ethics Board and operational approvals * Royal Columbian Hospital became the 9th global site activated in the Phase II CS-AKI trial * 4 Canadian sites are actively recruiting patients (Toronto General, St. Michael's, Calgary, RCH) Negative. 03/24/2026 - 09:13 AM TORONTO, March 24, 2026 (GLOBE NEWSWIRE) - Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement ("CTA") with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With the Clinical Trial Application (CTA) completed, RCH has now received final Research Ethics Board and operational approvals, including the final letter of authorization from Fraser Health. RCH will be the ninth site activated globally in the study and will be the fourth site to recruit patients in Canada. Toronto General Hospital, part of University Health Network, St. Michael's Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial. The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States. About Arch Biopartners Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury. Arch's development pipeline includes: * LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI. * Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI. * CKD Platform: next-generation therapeutics targeting chronic kidney disease. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide[1]. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development. For more details about the Company's science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news. The Company has 66,933,289 common shares outstanding. | Aaron Benson Director of Communications Arch Biopartners, Inc. 647-428-7031 | / | | / | / | Send a message or subscribe for trial updates and company news at www.archbiopartners.com/contact-us Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company's future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in the Company's most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company's most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedarplus.ca. References: * Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461 - 2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext The scientific and medical content of this release has been reviewed and approved by the Company's Chief Science Officer. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Faq. What does the Clinical Trial Agreement with Fraser Health mean for Arch Biopartners (ACHFF)? It enables Royal Columbian Hospital to prepare for patient recruitment in the Phase II CS-AKI trial. According to the company, RCH now has final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health, supporting site activation. How many sites are active in Arch Biopartners' (ACHFF) Phase II LSALT CS-AKI trial after Royal Columbian Hospital activation? Royal Columbian Hospital is the ninth site activated globally in the study. According to the company, RCH is also the fourth site in Canada to reach activation and prepare for recruitment. Which Canadian hospitals are currently recruiting for Arch Biopartners' (ACHFF) Phase II CS-AKI trial? Toronto General Hospital, St. Michael's Hospital, University of Calgary, and now Royal Columbian Hospital are recruiting. According to the company, those four Canadian centres are actively enrolling new patients into the trial. What approvals did Royal Columbian Hospital receive to start recruitment for the ACHFF Phase II trial? RCH received final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health. According to the company, these approvals complete site readiness for recruitment and study start-up activities. Will Arch Biopartners (ACHFF) add more sites in Canada and the US for the Phase II CS-AKI trial? The company is progressing feasibility and start-up discussions with additional cardiac surgery centres in Canada and the United States. According to the company, those discussions aim to expand site activation beyond the current nine global sites.

Black Press Media
Mar 14th, 2026
$1.3M funding will help more Indigenous elders in Chilliwack with at-home care

$1.3M funding will help more Indigenous elders in Chilliwack with at-home care. Published 8:45 am Saturday, March 14, 2026 An at-home program that offers care to Indigenous elders in the Fraser Valley will be expanding, with the main focus on Chilliwack, thanks to $1.3 million in new funding. The Indigenous Caregiver Support Model (ICSM) is a home-based program that supports elders with "complex needs to age safely at home and in their community," according to a Fraser Health press release. It is one of five programs in B.C. benefitting from a total of $6.3 million in funding from Health Research BC over the next three years. The funding will advance research to help B.C. seniors age comfortably in their own home. The ICSM program was launched in 2023 as a pilot project and has supported 33 elders and their caregivers in the Eastern Fraser Valley, including Chilliwack. Its aim is to reduce caregiver strain and improve elder wellbeing by providing culturally safe, coordinated in-home support, training, and financial assistance for Indigenous families caring for elders. It is co-designed by Fraser Health Indigenous Health, Stó:lō Service Agency, First Nations Health Authority, and Métis Nation British Columbia. "This model is an example of what is possible when care is built on relationships, trust and community," said Amanda LaBoucane, interim vice president, Indigenous Health and Cultural Safety. "Many elders and caregivers in the Chilliwack area have experienced firsthand the impacts of residential schools and the child welfare system. By strengthening caregiver capacity and confidence while bridging into integrated clinical care teams run by and for Indigenous people, we see improved health and wellness and stronger relationships within and between communities." The program is currently operating in the Fraser Valley, including Chilliwack, but the expansion will focus on urban Chilliwack as that is an identified need, said Carrie Stefanson with Fraser Health. Caregivers receive skills training and an honorarium to help reduce the economic strain of caregiving, while elders receive regular home visits from Indigenous-led clinical teams who provide culturally safe, relationship-based care, rooted in trust, kindness and respect, according to a Fraser Health.

Fraser Health
Sep 12th, 2024
Leveraging artificial intelligence to assist with scheduling

Fraser Health has partnered with Deloitte Canada to develop and launch scheduling tools that leverage artificial intelligence (AI) and machine-learning solutions to accurately forecast the waves in demand Fraserhealth see in the health system.

Government of British Columbia
Aug 22nd, 2024
Permanent supportive, complex-care homes open in Fraser Valley

For people not already connected to services, Fraser Health will work in partnership with Coast Mental Health to provide on-site clinical supports, including services from a psychiatric nurse, community nurse, licensed practical nurse, social worker and traditional wellness practitioners.

Daily Hive
Sep 12th, 2023
Construction begins on Surrey's new $2.9 billion Cloverdale hospital

Through a procurement process, Fraser Health has selected Ellis-Don Design Build to design and build the new facility through a design-build agreement.